Browse > Article
http://dx.doi.org/10.14348/molcells.2015.2340

Obatoclax Regulates the Proliferation and Fusion of Osteoclast Precursors through the Inhibition of ERK Activation by RANKL  

Oh, Ju Hee (Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University)
Lee, Jae Yoon (Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University)
Park, Jin Hyeong (Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University)
No, Jeong Hyeon (Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University)
Lee, Na Kyung (Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University)
Publication Information
Molecules and Cells / v.38, no.3, 2015 , pp. 279-284 More about this Journal
Abstract
Obatoclax, a pan-Bcl2 inhibitor, shows antitumor activities in various solid malignancies. Bcl2-deficient mice have shown the importance of Bcl2 in osteoclasts, as the bone mass of the mice was increased by the induced apoptosis of osteoclasts. Despite the importance of Bcl2, the effects of obatoclax on the proliferation and differentiation of osteoclast precursors have not been studied extensively. Here, we describe the anti-proliferative effects of obatoclax on osteoclast precursors and its negative role on fusion of the cells. Stimulation with low doses of obatoclax significantly suppressed the proliferation of osteoclast precursors in a dose-dependent manner while the apoptosis was markedly increased. Its stimulation was sufficient to block the activation of ERK MAP kinase by RANKL. The same was true when PD98059, an ERK inhibitor, was administered to osteoclast precursors. The activation of JNK1/2 and p38 MAP kinase, necessary for osteoclast differentiation, by RANKL was not affected by obatoclax. Interestingly, whereas the number of TRAP-positive mononuclear cells was increased by both obatoclax and PD98059, fused, multinucleated cells larger than $100{\pm}m$ in diameter containing more than 20 nuclei were completely reduced. Consistently, obatoclax failed to regulate the expression of osteoclast marker genes, including c-Fos, TRAP, RANK and CtsK. Instead, the expression of DC-STAMP and Atp6v0d2, genes that regulate osteoclast fusion, by RANKL was significantly abrogated by both obatoclax and PD98059. Taken together, these results suggest that obatoclax down-regulates the proliferation and fusion of osteoclast precursors through the inhibition of the ERK1/2 MAP kinase pathway.
Keywords
ERK1/2 MAP kinase; fusion; obatoclax; osteoclast precursors; proliferation;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Anderson, D.M., Maraskovsky, E., Billingsley, W.L., Dougall, W.C., Tometsko, M.E., Roux, E.R., Teepe, M.C., DuBose, R.F., Cosman, D., and Galibert, L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179   DOI   ScienceOn
2 Blair, H.C. (1998). How the osteoclast degrades bone. Bioessays 20, 837-848   DOI
3 Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.   DOI   ScienceOn
4 Campa's, C., Cosialls, A.M., Barragn, M., Iglesias-Serret, D., Santidrian, A.F., Coll-Mulet, L., de Frias, M., Domingo, A., Pons, G., and Gil, J. (2006). Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol. 34, 1663-1669   DOI   ScienceOn
5 Choi, J., Choi, S.Y., Lee, S.Y., Lee, J.Y., Kim, H.S., Lee, S.Y., and Lee, N.K. (2013). Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DCSTAMP/CtsK and TRAP pathway. Cell. Signal. 25, 1222-1227   DOI   ScienceOn
6 David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H., and Wagner, E.F. (2002). JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J. Cell Sci. 115, 4317-4325.   DOI   ScienceOn
7 de Vries, T.J., Schoenmaker, T., Beertsen, W., van der Neut, R., and Everts, V. (2005). Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J. Cell. Biochem. 94, 954-966.   DOI   ScienceOn
8 Harada, S., and Rodan, G.A. (2003). Control of osteoblast function and regulation of bone mass. Nature 423, 349-355.   DOI   ScienceOn
9 Hartgers, F.C., Vissers, J.L., Looman, M.W., van Zoelen, C., Huffine, C., Figdor, C.G., and Adema, G.J. (2000). DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur. J. Immunol. 30, 3585-3590.   DOI
10 Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L., and Korsmeyer, S.J. (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75, 241-251.   DOI   ScienceOn
11 Hwang, J.J., Kuruvilla, J., Mendelson, D., Pishvaian, M.J., Deeken, J.F., Siu, L.L., Berger, M.S., Viallet, J., and Marshall, J.L. (2010). Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 16, 4038-4045.   DOI   ScienceOn
12 Ishii, M., Iwai, K., Koike, M., Ohshima, S., Kudo-Tanaka, E., Ishii, T., Mima, T., Katada, Y., Miyatake, K., Uchiyama, Y., and Saeki, Y. (2006). RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J. Bone Miner. Res. 21, 965-976.   DOI   ScienceOn
13 Kim, H.S., and Lee, N.K. (2014). Gene expression profiling in osteoclast precursors by insulin using microarray analysis. Mol. Cells 30, 827-832.
14 Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata, K., Iijima, T., Horiuchi, M., Matsusaki, H., et al. (2004). RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200, 941-946.   DOI   ScienceOn
15 Kim, K., Lee, S.H., Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via upregulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DCSTAMP). Mol. Endocrinol. 22, 176-185.   DOI   ScienceOn
16 Kim, P.S., Jochems, C., Grenga, I., Donahue, R.N., Tsang, K.Y., Gulley, J.L., Schlom, J., and Farsaci, B. (2014). Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy, J. Immunol. 192, 2622-2633.   DOI   ScienceOn
17 Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., et al. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420.   DOI   ScienceOn
18 Lee, J.Y., and Lee, N.K. (2014). Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. Life Sci. 114, 57-61.   DOI   ScienceOn
19 Lee, S.H., Rho, J., Jeong, D., Sul, J.Y., Kim, T., Kim, N., Kang, J.S., Miyamoto, T., Suda, T., Lee, S.K., et al. (2006). v-ATPase V0 subunit d2-deficient mice exhibit impaired steoclast fusion and increased bone formation. Nat. Med. 12, 1403-1409   DOI
20 Li, X., Udagawa, N., Itoh, K., Suda, K., Murase, Y., and Nishihara, T. (2002). p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105-3113.   DOI
21 Rho, J., Altmann, C.R., Socci, N.D., Merkov, L., Kim, N., So, H., Lee, O., Takami, M., Brivanlou, A.H., and Choi, Y. (2002). Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell. Biol. 21, 541-549   DOI   ScienceOn
22 Mansky, K.C., Sankar, U., Han, J., and Ostrowski, M.C. (2002). Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-B ligand signaling. J. Biol. Chem. 277, 11077-11083.   DOI   ScienceOn
23 Nishi, T., Kawasaki-Nishi, S., and Forgac, M. (2003). Expression and function of the mouse V-ATPase d subunit isoforms. J. Biol. Chem. 278, 46396-46402.   DOI   ScienceOn
24 Paik, P.K., Rudin, C.M., Brown, A., Rizvi, N.A., Takebe, N., Travis, W., James, L., Ginsberg, M.S., Juergens, R., Markus, S., et al. (2010). A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother. Pharmacol. 66, 1079-1085.   DOI
25 Rodan, G.A., and Martin, T.J. (2000) Therapeutic approaches to bone diseases. Science 289, 1508-1514.   DOI
26 Staege, H., Brauchlin, A., Schoedon, G., and Schaffner, A. (2001). Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages. Immunogenetics 53, 105-113.   DOI
27 Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508   DOI   ScienceOn
28 Trudel, S., Li, Z.H., Rauw, J., Tiedemann, R.E., Wen, X.Y., and Stewart, A.K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438   DOI   ScienceOn
29 Wei, S., Wang, M.W., Teitelbaum, S.L., and Ross, F.P. (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277, 6622-6630.   DOI   ScienceOn
30 Vignery, A. (2000). Osteoclasts and giant cells: macrophagemacrophage fusion mechanism. Int. J. Exp. Pathol. 81, 291-304.   DOI
31 Wong, B.R., Josien, R., Lee, S.Y., Sauter, B., Li, H.L., Steinman, R.M., and Choi, Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cellspecific survival factor. J. Exp. Med. 186, 2075-2080.   DOI
32 Wu, H., Xu, G., and Li, Y.P. (2009). Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J. Bone Miner. Res. 24, 871-885.   DOI   ScienceOn
33 Xing, L., Xiu, Y., and Boyce, B.F. (2012). Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J. Orthop. 3, 212-222.   DOI   ScienceOn
34 Yamashita, J., Datta, N.S., Chun, Y.H., Yang, D.Y., Carey, A.A., Kreider, J.M., Goldstein, S.A., and McCauley, L.K. (2008). Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J. Bone Miner. Res. 23, 621-632.
35 Yang, J., Zhang, X., Wang, W., and Liu, J. (2010). Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem. Funct. 28, 334-341.   DOI   ScienceOn
36 Zhang, C., Dou, C.E., Xu, J., and Dong, S. (2014). DC-STAMP, the key fusion-mediating molecule in osteoclastogenesis. J. Cell. Physiol. 229, 1330-1335.   DOI   ScienceOn